Tag Archives: SPEXIS
BIOTECH
Spexis provides business update and announces financial results for the first half of 2023
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases...
Read moreBIOTECH
Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases...
Read moreBIOTECH
Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today...
Read moreBIOTECH
Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®
Ad hoc announcement pursuant to Art. 53 LR SGI debt facility to provide Spexis up...
Read more